ARTH
Price:
$0.2798
Market Cap:
$1.24M
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2013-01-02
Stock Exchange
PNK
Ticker
ARTH
According to Arch Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 121.05%. This represents a change of 306.00% compared to the average of 29.81% of the last 4 quarters.
The mean historical ROE of Arch Therapeutics, Inc. over the last ten years is 47.36%. The current 121.05% ROE has changed 155.62% with respect to the historical average. Over the past ten years (40 quarters), ARTH's ROE was at its highest in in the December 2019 quarter at 1.65%. The ROE was at its lowest in in the March 2016 quarter at -1066.30%.
Average
47.36%
Median
97.49%
Minimum
-354.02%
Maximum
640.48%
Discovering the peaks and valleys of Arch Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 139.53%
Maximum Annual ROE = 640.48%
Minimum Annual Increase = -262.00%
Minimum Annual ROE = -354.02%
Year | ROE | Change |
---|---|---|
2023 | 93.01% | -8.80% |
2022 | 101.98% | -84.08% |
2021 | 640.48% | 139.53% |
2020 | 267.39% | -20.74% |
2019 | 337.35% | -195.29% |
2018 | -354.02% | 1.20% |
2017 | -349.82% | 84.53% |
2016 | -189.57% | -0.95% |
2015 | -191.38% | -262.00% |
2014 | 118.14% | -111.92% |
The current ROE of Arch Therapeutics, Inc. (ARTH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
278.49%
5-year avg
288.04%
10-year avg
47.36%
Arch Therapeutics, Inc.’s ROE is greater than Bioasis Technologies Inc. (0%), greater than Antibe Therapeutics Inc. (-49.77%), less than Awakn Life Sciences Corp. (231.42%), greater than Cellectis S.A. (-75.49%), less than Adynxx, Inc. (0%), greater than AVAX Technologies, Inc. (0%), greater than BioCardia, Inc. (-344.15%), less than Adial Pharmaceuticals, Inc. WT EXP 073123 (1.00%), greater than null (-256.25%),
Company | ROE | Market cap |
---|---|---|
0% | $27.64M | |
-49.77% | $11.45M | |
231.42% | $2.71M | |
-75.49% | $183.12M | |
0% | $600.00 | |
0% | $6.89K | |
-344.15% | $10.12K | |
1.00% | $0 | |
-256.25% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arch Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arch Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Arch Therapeutics, Inc.'s ROE?
How is the ROE calculated for Arch Therapeutics, Inc. (ARTH)?
What is the highest ROE for Arch Therapeutics, Inc. (ARTH)?
What is the 3-year average ROE for Arch Therapeutics, Inc. (ARTH)?
What is the 5-year average ROE for Arch Therapeutics, Inc. (ARTH)?
How does the current ROE for Arch Therapeutics, Inc. (ARTH) compare to its historical average?